Strong revenue momentum Corcept demonstrates robust and recent revenue growth with multiple quarters showing solid top-line performance, including a 31.7% year-over-year revenue increase in the latest quarter and overall revenue in the hundreds of millions range, indicating a healthy customer base and potential for upsell to existing pharma partners.

Strategic partnerships Recent collaboration with Clinigen to enable access to relacorilant via International Pharmacy suggests ongoing partner-driven commercialization and distribution opportunities that can be expanded with additional global access and dosing programs.

Clinical expansion With more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology, and upcoming pivotal data presentations (for example ROSELLA in platinum-resistant ovarian cancer), there are avenues to align services, CRO support, and field medical affairs partnerships for sponsor-led trials and companion diagnostics.

Market positioning As a specialized cortisol modulation company with FDA-approved receptor blocker for Cushing’s syndrome and a portfolio of proprietary modulators, Corcept presents opportunities to offer early-access programs, biomarker services, and regulatory strategy support to widen adoption and optimize patient access.

Operational scale Headcount in the mid‑hundreds and a midsize market cap position imply room for scalable collaborations, such as contract manufacturing, supply chain optimization, and tech-enabled sales/CRM deployments that can support broader geographic reach and faster cycle times for partner projects.